← Eichor
Study identifier: NCT07068529 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC

Condition: Colorectal Cancer  ·  Sponsor: Shanghai Minimally Invasive Surgery Center

PhaseN/A
Planned participants250
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This prospective clinical observational study aims to construct a metabolite database specifically for colorectal cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in colorectal cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.

This description comes directly from the study's public registry record.

Talk to the study team

Jing Sun  ·  +86-13524284622  ·  sj117788@rjh.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin hospital Shanghai Jiaotong University, School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07068529